These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30867522)

  • 1. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis.
    Bradley A; Van Der Meer R
    Sci Rep; 2019 Mar; 9(1):4354. PubMed ID: 30867522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
    Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
    PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.
    Aliseda D; Martí-Cruchaga P; Zozaya G; Blanco N; Ponz M; Chopitea A; Rodríguez J; Castañón E; Pardo F; Rotellar F
    BJS Open; 2024 Sep; 8(5):. PubMed ID: 39329454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis.
    Bradley A; Van Der Meer R
    PLoS One; 2019; 14(2):e0212805. PubMed ID: 30817807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
    de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
    Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
    Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
    World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
    Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
    Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
    Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant therapy vs. upfront resection for resectable pancreatic cancer].
    Strobel O; Büchler MW
    Chirurg; 2017 Jul; 88(7):619. PubMed ID: 28573533
    [No Abstract]   [Full Text] [Related]  

  • 16. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
    Unno M; Hata T; Motoi F
    Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis.
    de Geus SW; Evans DB; Bliss LA; Eskander MF; Smith JK; Wolff RA; Miksad RA; Weinstein MC; Tseng JF
    Eur J Surg Oncol; 2016 Oct; 42(10):1552-60. PubMed ID: 27570116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
    Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
    Front Oncol; 2021; 11():812102. PubMed ID: 35083158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.